Ambience Healthcare vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ambience Healthcare raised $370M (~$1B valuation) and hit $30M ARR with ambient AI documentation across 100+ specialties, eliminating the documentation burden driving clinician burnout.
About
Ambience Healthcare was founded in 2020 in San Francisco with a mission to eliminate the documentation burden that drives clinician burnout and degrades patient care quality across health systems. The company builds ambient AI documentation technology that listens to clinical encounters across more than 100 medical and surgical specialties, generating accurate, complete clinical notes in the background without requiring clinicians to dictate or type. Ambience's core technology leverages large language models purpose-trained on clinical language, specialty-specific note structures, and electronic health record formatting requirements to produce documentation that is ready for review with minimal editing.\n\nAmbience's platform is deployed across health systems ranging from large academic medical centers to independent practices, covering more than 100 specialties including primary care, surgery, oncology, behavioral health, and pediatrics. Unlike narrower documentation tools that focus on a single specialty or encounter type, Ambience's breadth allows health systems to deploy a single solution enterprise-wide. The platform integrates with major EHR systems including Epic and Cerner, embedding documentation into existing clinical workflows without requiring behavior change from clinicians. Ambience achieved approximately $30 million in annual recurring revenue as of May 2025.\n\nAmbience Healthcare has raised approximately $370 million in total funding, approaching a $1 billion valuation, from investors including Andreessen Horowitz and other leading healthcare-focused venture firms. The company competes with Nuance DAX, Suki, and Nabla in the ambient documentation space but differentiates through its specialty breadth, enterprise EHR integration depth, and strong health system relationships. As health systems face escalating clinician burnout and documentation-driven inefficiency, Ambience's full-enterprise approach positions it as a platform of record for ambient clinical intelligence.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.